For the 12th consecutive year, Global Competition Review has named Davies an “Elite” Canadian firm in its annual listing of the world’s top competition practices – the highest category awarded in the jurisdiction.
The guide commends our role in a “long list of global deals” over the past year, as well as our continued track record of success in competition litigation. A sampling of our recent notable work includes acting for Celgene Corp. in its proposed US$74-billion purchase by Bristol-Myers Squibb Co.; acting for Monsanto on its €57-billion sale to Bayer, Pfizer on its proposed deal with GlaxoSmithKline related to their consumer healthcare businesses; and the Liquor Control Board of Ontario in successfully defending a multi-billion dollar class action alleging a price-fixing conspiracy.
Compiled independently, the GCR 100 provides a qualitative analysis of the law firms doing the most important competition and antitrust work around the world.
Disclosure Interrupted: CSA Pauses Climate and Diversity Disclosure Rules
Apr. 28, 2025 - The Canadian Securities Administrators (CSA) is pausing its work on climate-related and diversity-related disclosure rules in order “to support Canadian markets and issuers as they adapt to the recent developments in the U.S. and globally. ” Consistent with the CSA’s recent regulatory shift...
Canada Updates National Security Review Guidelines Amid Trade Tensions
Mar. 06, 2025 - Canada’s Minister of Innovation, Science and Industry (Minister), François-Philippe Champagne, has announced an update to the Investment Canada Act (ICA) National Security Review Guidelines (Guidelines) to expressly include “the potential of the investment to undermine Canada’s economic...
